iTeos Therapeutics announced the appointment of David Feltquate, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Feltquate will be responsible for overseeing the Company’s clinical development and regulatory strategies. Prior to joining iTeos, Feltquate was Chief Medical Officer at Palleon Pharmaceuticals where he oversaw the clinical strategy and development of its glyco-immunology therapeutics pipeline.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITOS:
- iTeos Therapeutics announces first patient dosed in GALAXIES Lung-301 study
- iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK
- iTeos Therapeutics, GSK initiate GALAXIES Lung-301 Phase 3 study
- iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer